The Ability of Virulence Factor Expression by Pseudomonas aeruginosa to Predict Clinical Disease in Hospitalized Patients

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Ledizet, Michel ^a   Murray, Thomas S ^b,c   Puttagunta, Sailaja ^b,d   Slade, Martin D ^b   Quagliarello, Vincent J ^b   Kazmierczak, Barbara I ^b  

^a L2 Diagnostics LLC   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Quinnipiac University   (United States)

^d Durata Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HOST FACTOR; VIRULENCE FACTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; CATHETER INFECTION; CHILD; COHORT ANALYSIS; DIABETES MELLITUS; FEMALE; HOSPITAL PATIENT; HUMAN; INFANT; INFECTION RISK; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRESCHOOL CHILD; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RISK FACTOR; SCHOOL CHILD; SOFT TISSUE INFECTION; URINARY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COLONY COUNT, MICROBIAL; FEMALE; HOSPITALIZATION; HOST-PATHOGEN INTERACTIONS; HUMANS; INFANT; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RISK FACTORS; VIRULENCE FACTORS; YOUNG ADULT;

ANIMALIA; BACTERIA (MICROORGANISMS); PSEUDOMONAS AERUGINOSA;

EID: 84869051871     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049578     Document Type: Article

References (52)

1. Wenzel RP, Edmond MB, (2001) The impact of hospital-acquired bloodstream infections. Emerging Infect Dis 7: 174-177.
2. Gaynes R, Edwards JR, National Nosocomial Infections Surveillance System, (2005) Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 41: 848-854.
3. Chastre J, Fagon JY, (2002) Ventilator-associated pneumonia. Am J Respir Crit Care Med 165: 867-903.
4. Lambert PA, (2002) Mechanisms of antibiotic resistance of Pseudomonas aeruginosa. J Royal Soc Med 95: 22-26.
5. Cortes P, Mariscal D, Valles J, Rello J, Coll P, (2001) Presence of polyclonal Pseudomonas aeruginosa in an intensive care unit: a 27-month prospective study on molecular epidemiology. Infect Control Hosp Epidemiol 22: 720-723.
6. Parsek MR, Singh PK, (2003) Bacterial biofilms: an emerging link to disease pathogenesis. Ann Rev Microbiol 57: 677-701.
7. Talon D, Mulin B, Rouget C, Bailly P, Thouverez M, et al. (1998) Risks and routes for ventilator-associated pneumonia with Pseudomonas aeruginosa. Am J Respir Crit Care Med 157: 978-984.
8. Hauser AR, (2009) The type III secretion system of Pseudomonas aeruginosa: infection by injection. Nat Rev Microbiol 7: 654-665.
9. El Solh AA, Akinnusi ME, Wiener-Kronish JP, Lynch SV, Pineda LA, et al. (2008) Persistent infection with Pseudomonas aeruginosa in ventilator-associated pneumonia. Am J Respir Crit Care Med 178: 513-519.
10. Hauser A, Cobb E, Bodi M, Mariscal D, Valles J, et al. (2002) Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Crit Care Med 30: 521-528.
11. Roy-Burman A, Savel RH, Racine S, Swanson BL, Revadigar NS, et al. (2001) Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J Infect Dis 183: 1767-1774.
12. Vance RE, Rietsch A, Mekalanos JJ, (2005) Role of the Type III secreted exoenzymes S, T and Y in systemic spread of Pseudomonas aeruginosa PA01 in vivo. Infect Immun 73: 1705-1713.
13. Lee VT, Smith RS, Tummler B, Lory S, (2005) Activities of Pseudomonas aeruginosa effectors secreted by the Type III secretion system in vitro and during infection. Infect Immun 73: 1695-1705.
14. Shaver CM, Hauser AR, (2004) Relative contributions of Pseudomonas aeruginosa ExoU, ExoS and ExoT to virulence in the lung. Infect Immun 72: 6969-6977.
15. El-Solh AA, Hattemer A, Hauser AR, Alhajhusain A, Vora H, (2012) Clinical outcomes of type III Pseudomonas aeruginosa bacteremia. Crit Care Med 40: 1157-1163.
16. Nguyen D, Emond MJ, Mayer-Hamblett N, Saiman L, Marshall BC, et al. (2007) Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology 42: 533-541.
17. Mahenthiralingam E, Campbell ME, Speert DP, (1994) Nonmotility and phagocytic resistance of Pseudomonas aeruginosa isolates from chronically colonized patients with cystic fibrosis. Infect Immun 62: 596-605.
18. Arora SK, Neely AN, Blair B, Lory S, Ramphal R, (2005) Role of motility and flagellin glycosylation in the pathogenesis of Pseudomonas aeruginosa burn wound infections. Infect Immun 73: 4395-4398.
19. Balloy V, Verma A, Kuravi SK, Si-Tahar M, Chignard M, et al. (2007) The role of flagellin versus motility in acute lung disease caused by Pseudomonas aeruginosa. J Infect Dis 196: 289-296.
20. Feldman M, Bryan R, Rajan S, Scheffler L, Brunnert S, et al. (1998) Role of flagella in pathogenesis of Pseudomonas aeruginosa pulmonary infection. Infect Immun 66: 43-51.
21. Tang H, Kays M, Prince A, (1995) Role of Pseudomonas aeruginosa pili in acute pulmonary infection. Infect Immun 63: 1278-1285.
22. Hamood AN, Griswold JA, Duhan CM, (1996) Production of extracellular virulence factors by Pseudomonas aeruginosa isolates obtained from tracheal, urinary tract, and wound infections. J Surg Res 61: 425-432.
23. Mun JJ, Tam C, Kowbel D, Hawgood S, Barnett MJ, et al. (2009) Clearance of Pseudomonas aeruginosa from a healthy ocular surface involves surfactant protein D and is compromised by bacterial elastase in a murine null-infection model. Infect Immun 77: 2392-2398.
24. Preston M, Seed P, Toder D, Iglewski B, Ohman D, et al. (1997) Contribution of Proteases and LasR to the Virulence of Pseudomonas aeruginosa during Corneal Infections. Infection and Immunity 65: 3086-3090.
25. Woods DE, Schaffer MS, Rabin HR, Campbell GD, Sokol PA, (1986) Phenotypic comparison of Pseudomonas aeruginosa strains isolated from a variety of clinical sites. J Clin Microbiol 24: 260-264.
26. He J, Baldini RL, Deziel E, Saucier M, Zhang Q, et al. (2004) The broad host range pathogen Pseudomonas aeruginosa strain PA14 carries two pathogenicity islands harboring plant and animal virulence genes. Proc Natl Acad Sci U S A 101: 2530-2535.
27. Battle SE, Meyer F, Rello J, Kung VL, Hauser AR, (2008) Hybrid pathogenicity island PAGI-5 contributes to the highly virulent phenotype of a Pseudomonas aeruginosa isolate in mammals. J Bacteriol 190: 7130-7140.
28. Kulasekara BR, Kulasekara HD, Wolfgang MC, Stevens L, Frank DW, et al. (2006) Acquisition and Evolution of the exoU Locus in Pseudomonas aeruginosa. J Bacteriol 188: 4037-4050.
29. Lee DG, Urbach JM, Wu G, Liberati NT, Feinbaum RL, et al. (2006) Genomic analysis reveals that Pseudomonas aeruginosa virulence is combinatorial. Genome Biol 7: R90.91-R90.14.
30. Wiehlmann L, Wagner G, Cramer N, Siebert B, Gudowius P, et al. (2007) Population structure of Pseudomonas aeruginosa. Proceedings of the National Academy of Sciences 104: 8101-8106.
31. Harrison EM, Carter ME, Luck S, Ou HY, Deng Z, et al. (2010) Pathogenicity islands PAPI-1 and PAPI-2 contribute individually and synergistically to the virulence of Pseudomonas aeruginosa strain PA14. Infect Immun 78: 1437-1446.
32. Mikkelsen H, Sivaneson M, Filloux A, (2011) Key two-component regulatory systems that control biofilm formation in Pseudomonas aeruginosa. Environ Microbiol 13: 1666-1681.
33. Hu H, Harmer C, Anuj S, Wainwright CE, Manos J, et al. (2012) Type 3 secretion system effector genotype and secretion phenotype of longitudinally collected Pseudomonas aeruginosa isolates from young children diagnosed with cystic fibrosis following newborn screening. Clin Microbiol Infect: no-no.
34. Jain M, Ramirez D, Seshadri R, Cullina JF, Powers CA, et al. (2004) Type III secretion phenotypes of Pseudomonas aeruginosa strains change during infection of individuals with Cystic Fibrosis. J Clin Microbiol 42: 5229-5237.
35. Hatcher L (1994) A Step-by-Step Approach Using the SAS System for Factor Analysis and Structural Equation Modeling. Cary, NC: SAS Institute, Inc.
36. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM, (1988) CDC definitions for nosocomial infections, 1988. Am J Infect Control 16: 128-140.
37. Li L, Ledizet M, Kar K, Koski RA, Kazmierczak BI, (2005) An indirect enzyme-linked immunosorbent assay for rapid and quantitative detection of type III virulence phenotypes of Pseudomonas aeruginosa isolates. Ann Clin Microbiol Antimicrobiol 4: 22-35.
38. Murray TS, Ledizet M, Kazmierczak BI, (2010) Swarming motility, secretion of type 3 effectors and biofilm formation phenotypes exhibited within a large cohort of Pseudomonas aeruginosa clinical isolates. J Med Microbiol 59: 511-520.
39. Merritt JH, Kadouri DE, Otoole GA (2005) Growing and analyzing static biofilms. In: Coico R, Kowalik T, Quarles J, Stevenson B, Taylor RK, editors. Current Protocols in Microbiology: John Wiley & Sons, Inc. 1B.1.1-1B.1.17.
40. Caballero AR, Moreau JM, Engel LS, Marquart ME, Hill JM, et al. (2001) Pseudomonas aeruginosa protease IV enzyme assays and comparison to the Pseudomonas proteases. Anal Biochem 290: 330-337.
41. Pier GB, Ramphal R (2010) Pseudomonas aeruginosa. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 7th ed. Philadelphia, PA: Churchill Livingstone Elsevier. 2835-2860.
42. Carter MQ, Chen J, Lory S, (2010) The Pseudomonas aeruginosa pathogenicity island PAPI-1 is transferred via a novel type IV pilus. J Bacteriol 192: 3249-3258.
43. Wolfgang MC, Lee VT, Gilmore ME, Lory S, (2003) Coordinate regulation of bacterial genes by a novel adenylate cyclase signaling pathway. Devlop Cell 4: 253-263.
44. Mittal R, Aggarwal S, Sharma S, Chhibber S, Harjai K, (2009) Urinary tract infections caused by Pseudomonas aeruginosa: a minireview. J Infect Public Health 2: 101-111.
45. Kumar R, Chhibber S, Harjai K, (2009) Quorum sensing is necessary for the virulence of Pseudomonas aeruginosa during urinary tract infection. Kidney Int 76: 286-292.
46. Miyata S, Casey M, Frank DW, Ausubel FM, Drenkard E, (2003) Use of the Galleria mellonella Caterpillar as a Model Host To Study the Role of the Type III Secretion System in Pseudomonas aeruginosa Pathogenesis. Infect Immun 71: 2404-2413.
47. National Nosocomial Infection Surveillance System, (2004) National Nosocomial Infection Surveillance (NNIS) System report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 32: 470-485.
48. Arnoldo A, Curak J, Kittanakom S, Chevelev I, Lee VT, et al. (2008) Identification of small molecule inhibitors of Pseudomonas aeruginosa exoenzyme S using a yeast phenotypic screen. PLoS Genet 4: e1000005.
49. Lee VT, Pukatzki S, Sato H, Kikawada E, Kazimirova AA, et al. (2007) Pseudolipasin A is a specific inhibitor for phospholipase A2 activity of Pseudomonas aeruginosa cytotoxin ExoU. Infect Immun 75: 1089-1098.
50. Sawa T, Yahr TL, Ohara M, Kurahashi K, Gropper MA, et al. (1999) Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury. Nat Med 5: 392-398.
51. Holder IA, Neely AN, Frank DW, (2001) PcrV immunization enhances survival of burned Pseudomonas aeruginosa-infected mice. Infect Immun 69: 5908-5910.
52. Francois B, Luyt CE, Dugard A, Wolff M, Diehl JL, et al. (2012) Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: A randomized,double-blind, placebo-controlled trial*. Crit Care Med 40: 2320-2326.